

Beth A Davison

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8317899/beth-a-davison-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98 papers	4,929 citations	38 h-index	69 g-index
102 ext. papers	6,003 ext. citations	8 avg, IF	4.89 L-index

#	Paper	IF	Citations
98	Worsening renal function in acute heart failure in the context of diuretic response. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	1
97	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021 , 9, 890-903	7.9	0
96	Noninvasive measure of treatment response in non-alcoholic steatohepatitis: Insights from EMMINENCE and meta-analysis. <i>JGH Open</i> , 2021 , 5, 740-749	1.8	1
95	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021 , 27, 808-811	3.3	0
94	N-terminal pro BNP and galectin-3 are prognostic biomarkers of acute heart failure in sub-Saharan Africa: lessons from the BAHEF trial. <i>ESC Heart Failure</i> , 2021 , 8, 74-84	3.7	2
93	Is acute heart failure a distinctive disorder? An analysis from BIOSAT-CHF. <i>European Journal of Heart Failure</i> , 2021 , 23, 43-57	12.3	5
92	Clinical characteristics and outcomes of black African heart failure patients with preserved, mid-range, and reduced ejection fraction: a post hoc analysis of the THESUS-HF registry. <i>ESC Heart Failure</i> , 2021 , 8, 238-249	3.7	0
91	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , 2021 , 23, 58-67	12.3	5
90	Differences in socio-demographic and risk factor profile, clinical presentation, and outcomes between patients with and without RHD heart failure in Sub-Saharan Africa: results from the THESUS-HF registry. <i>Cardiovascular Diagnosis and Therapy</i> , 2021 , 11, 980-990	2.6	
89	Early intravenous nitroglycerin use in prehospital setting and in the emergency department to treat patients with acute heart failure: Insights from the EAHFE Spanish registry. <i>International Journal of Cardiology</i> , 2021 , 344, 127-134	3.2	0
88	Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. <i>Journal of Hepatology</i> , 2020 , 73, 1322-1332	13.4	87
87	Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. <i>Journal of Hepatology</i> , 2020 , 72, 613-626	13.4	84
86	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020 , 22, 315-329	12.3	16
85	Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. <i>European Journal of Heart Failure</i> , 2020 , 22, 683-691	12.3	19
84	Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2. <i>JACC: Heart Failure</i> , 2020 , 8, 999-1008	7.9	0
83	Mega-trials in heart failure: effects of dilution in examination of new therapies. <i>European Journal of Heart Failure</i> , 2020 , 22, 1698-1707	12.3	6
82	Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. <i>European Journal of Heart Failure</i> , 2019 , 21, 1459-1467	12.3	13

81	Effects of Serelaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019 , 381, 716-726	59.2	92
80	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2019 , 25, 866-874	3.3	7
79	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. <i>ESC Heart Failure</i> , 2019 , 6, 1188-1198	3.7	13
78	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1561-1570	12.3	4
77	Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. <i>International Journal of Cardiology</i> , 2018 , 253, 91-96	3.2	2
76	Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. <i>International Journal of Cardiology</i> , 2018 , 258, 185-191	3.2	78
75	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. <i>Clinical Research in Cardiology</i> , 2018 , 107, 170-181	6.1	22
74	Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?. <i>European Journal of Heart Failure</i> , 2018 , 20, 317-322	12.3	14
73	Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data. <i>Circulation: Heart Failure</i> , 2018 , 11, e004644	7.6	38
72	Prevalence, clinical characteristics and outcomes of valvular atrial fibrillation in a cohort of African patients with acute heart failure: insights from the THESUS-HF registry. <i>Cardiovascular Journal of Africa</i> , 2018 , 29, 139-145	0.7	4
71	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	9
70	A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. <i>European Journal of Heart Failure</i> , 2017 , 19, 1001-1010	12.3	57
69	Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. <i>Clinical Research in Cardiology</i> , 2017 , 106, 444-456	6.1	4
68	Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). <i>European Journal of Heart Failure</i> , 2017 , 19, 733-747	12.3	21
67	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. <i>Heart</i> , 2017 , 103, 407-413	5.1	42
66	Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. <i>European Journal of Heart Failure</i> , 2017 , 19, 728-738	12.3	24
65	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , 2017 , 19, 800-809	12.3	91
64	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017 , 38, 2364-2373	9.5	72

63	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. <i>JACC: Heart Failure</i> , 2017 , 5, 507-517	7.9	49
62	Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017 , 190, 113-122	4.9	9
61	Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017 , 187, 62-69	4.9	6
60	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. <i>European Journal of Heart Failure</i> , 2017 , 19, 1310-1320	12.3	39
59	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 281-293	3.9	6
58	Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. <i>Clinical Research in Cardiology</i> , 2017 , 106, 280-292	6.1	12
57	Symptoms and Signs of Heart Failure at Admission and Discharge and Outcomes in the Sub-Saharan Acute Heart Failure (THESUS-HF) Registry. <i>Journal of Cardiac Failure</i> , 2017 , 23, 739-742	3.3	12
56	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2017 , 23, 231-239	3.3	22
55	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). <i>American Journal of Cardiology</i> , 2017 , 119, 290-296	3	28
54	Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	10
53	Echocardiographic predictors of outcome in acute heart failure patients in sub-Saharan Africa: insights from THESUS-HF. <i>Cardiovascular Journal of Africa</i> , 2017 , 28, 60-67	0.7	7
52	In-hospital worsening heart failure in patients admitted for acute heart failure. <i>International Journal of Cardiology</i> , 2016 , 225, 353-361	3.2	11
51	Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. <i>European Journal of Heart Failure</i> , 2016 , 18, 1041-50	12.3	30
50	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	25
49	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. <i>International Journal of Cardiology</i> , 2016 , 204, 164-71	3.2	25
48	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2016 , 105, 727-37	6.1	14
47	Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. <i>Journal of Cardiac Failure</i> , 2016 , 22, 815-22	3.3	21
46	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. <i>Clinical Research in Cardiology</i> , 2016 , 105, 145-53	6.1	25

45	Optimizing clinical use of biomarkers in high-risk acute heart failure patients. <i>European Journal of Heart Failure</i> , 2016 , 18, 269-80	12.3	54
44	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. <i>European Journal of Heart Failure</i> , 2016 , 18, 830-9	12.3	51
43	Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial. <i>JACC: Heart Failure</i> , 2016 , 4, 591-599	7.9	40
42	Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial. <i>International Journal of Cardiology</i> , 2016 , 223, 967-975	3.2	6
41	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. <i>International Journal of Cardiology</i> , 2016 , 224, 231-239	3.2	42
40	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	55
39	Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. <i>European Journal of Heart Failure</i> , 2016 , 18, 641-9	12.3	20
38	Bi treatment with hydralazine/nitrates vs. placebo in Africans admitted with acute HEart Failure (BA-HEF). <i>European Journal of Heart Failure</i> , 2016 , 18, 1248-1258	12.3	10
37	Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies. <i>JACC: Heart Failure</i> , 2015 , 3, 395-403	7.9	36
36	Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2015 , 17, 1133-43	12.3	66
35	Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2015 , 17, 1262-70	12.3	75
34	Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , 2015 , 17, 697-706	12.3	21
33	Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. <i>Journal of Cardiac Failure</i> , 2015 , 21, 179-88	3.3	47
32	Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , 2015 , 17, 109-18	12.3	35
31	Gender differences in clinical characteristics and outcome of acute heart failure in sub-Saharan Africa: results of the THESUS-HF study. <i>Clinical Research in Cardiology</i> , 2015 , 104, 481-90	6.1	28
30	Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). <i>JACC: Heart Failure</i> , 2015 , 3, 193-201	7.9	62
29	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. <i>European Heart Journal</i> , 2014 , 35, 1284-93	9.5	205
28	Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond. <i>Current Heart Failure Reports</i> , 2014 , 11, 19-30	2.8	19

27	Renal function trajectories and clinical outcomes in acute heart failure. <i>Circulation: Heart Failure</i> , 2014 , 7, 59-67	7.6	47
26	Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1591-8	15.1	50
25	Prognostic significance of ECG abnormalities for mortality risk in acute heart failure: insight from the Sub-Saharan Africa Survey of Heart Failure (THESUS-HF). <i>Journal of Cardiac Failure</i> , 2014 , 20, 45-52	3.3	17
24	Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure--results from the relaxin for the treatment of patients with acute heart failure study. <i>Journal of Cardiac Failure</i> , 2014 , 20, 407-13	3.3	31
23	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. <i>European Journal of Heart Failure</i> , 2014 , 16, 614-24	12.3	57
22	Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 155-63	7.6	97
21	Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. <i>European Journal of Heart Failure</i> , 2014 , 16, 1362-71	12.3	22
20	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. <i>European Heart Journal</i> , 2014 , 35, 1041-50	9.5	72
19	Renal dysfunction in African patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2014 , 16, 718-28	12.3	7
18	Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. <i>European Journal of Heart Failure</i> , 2014 , 16, 1230-40	12.3	95
17	Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. <i>European Heart Journal</i> , 2013 , 34, 3128-36	9.5	48
16	The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 1973-81	15.1	131
15	Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 196-206	15.1	325
14	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2013 , 381, 29-39	4.0	693
13	Sex-specific acute heart failure phenotypes and outcomes from PROTECT. <i>European Journal of Heart Failure</i> , 2013 , 15, 1374-81	12.3	38
12	Readmission and death after an acute heart failure event: predictors and outcomes in sub-Saharan Africa: results from the THESUS-HF registry. <i>European Heart Journal</i> , 2013 , 34, 3151-9	9.5	58
11	Design of the RELAXin in acute heart failure study. <i>American Heart Journal</i> , 2012 , 163, 149-55.e1	4.9	53
10	The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. <i>Drug Safety</i> , 2012 , 35, 233-44	5.1	35

9	Evaluating treatment efficacy by multiple end points in phase II acute heart failure clinical trials: analyzing data using a global method. <i>Circulation: Heart Failure</i> , 2012 , 5, 742-9	7.6	33
8	The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. <i>European Journal of Heart Failure</i> , 2012 , 14, 605-12	12.3	99
7	Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. <i>Circulation: Heart Failure</i> , 2012 , 5, 54-62	7.6	288
6	The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. <i>Archives of Internal Medicine</i> , 2012 , 172, 1386-94		278
5	Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2011 , 100, 745-53	6.1	11
4	Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. <i>European Journal of Heart Failure</i> , 2011 , 13, 961-7	12.3	83
3	Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. <i>Circulation: Heart Failure</i> , 2011 , 4, 724-32	7.6	73
2	Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. <i>European Heart Journal</i> , 2011 , 32, 1519-34	9.5	74
1	Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). <i>Journal of Cardiac Failure</i> , 2008 , 14, 777-84	3.3	36